Advertisement
Dr. Guoqing, Jiang, Tianyin's Chairman and CEO, Mr. Allen Tang, assistantto the CEO, will be representing Tianyin Pharmaceutical at the conference andwill be available for one-on-one meetings with analysts and investorsthroughout the day.
Advertisement
Management will discuss the Company's current product portfolio,development pipeline, research and development platform, recent financialhighlights and its long-term growth strategy.
Participation is by invitation and registration is mandatory. For moreinformation on the conference contact your Roth representative or visithttp://www.roth.com .
About Roth China Discovery Tour
The 3rd Annual China Discovery Tour will feature more than 70 companies in7 cities throughout China, combining factory visits with managementpresentations in a mini conference format. This event is another chapter inRoth's growing commitment to China. Over the past two years Roth has takeninvestors on more than 60 company visits in mainland China and hosted close to200 China company presentations at its conferences. For more information aboutthis invite only event, please contact [email protected].
About Tianyin Pharmaceuticals
Tianyin is a manufacturer and supplier of modernized Traditional ChineseMedicine ("TCM") in China. It was established in 1994 and acquired by thecurrent management team in August 2003. It has a comprehensive productportfolio of 34 modernized TCMs in the market, 22 of which are listed in thehighly selective National Medicine Catalog of the National Medical InsuranceProgram. Tianyin owns and operates two GMP manufacturing facilities and an R&Dplatform supported by leading Chinese academic institutions. The Company has apipeline of 51 pharmaceutical products pending approval. Tianyin has anextensive nationwide distribution network throughout China with a sales forceof 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province withtwo manufacturing facilities and a total of 869 employees. Tianyin achievedrevenue of $20.4 million and net income of $3.95 million in FY2007 ending June30, 2007.
Safe Harbor Statement
The Statements which are not historical facts contained in this pressrelease are forward-looking statements that involve certain risks anduncertainties including but not limited to risks associated with theuncertainty of future financial results, additional financing requirements,development of new products, government approval processes, the impact ofcompetitive products or pricing, technological changes, the effect of economicconditions and other uncertainties detailed in the Company's filings with theSecurities and Exchange Commission.For more information, please contact: For the Company: Allen Tang, Ph.D., MBA, Assistant to the CEO Tel: +86-158-2122-5642 (China) Email: [email protected] Investors: HC International, Inc. Alan Sheinwald Tel: 1-914-669-0222 (US) Email: [email protected]
SOURCE Tianyin Pharmaceutical, Co., Inc.
